Program
desoxyepothilone B
Also written as “Utidelone Capsule”, “Utidelone” and “Utidelone in combination with capecitabine”.
Its studies are mostly in Breast Neoplasms · Ovarian Neoplasms · Carcinoma, Non-Small-Cell Lung · Brain Neoplasms · Lung Neoplasms, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Biostar Pharmaceuticals | 138 open or running | phase 3since Sep 29, 2014 | Sep 29, 2014 | Dec 1, 2026phase 2 · NCT06683703 |
| Bristol-Myers Squibb | 30 open or running | phase 2since Apr 5, 2004 | Feb 7, 2002 | none ahead |
| Biostar Pharma | 21 open or running | phase 2since Jan 7, 2025 | Dec 30, 2022 | Jan 15, 2027phase 2 · NCT06764940 |
| Hoffmann-La Roche | 10 open or running | phase 2since Jun 15, 2006 | Jun 15, 2006 | none ahead |
Also a collaborator on its studies: chengdu-biostar-pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Feb 7, 2002.
- Jun 15, 2006Hoffmann-La Roche's first study: phase 2 study in Breast NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT00337649 · 27 enrolled · Spain
- Sep 29, 2014Beijing Biostar Pharmaceuticals's first study: phase 3 study in Breast NeoplasmsNew to Beijing Biostar PharmaceuticalsBeijing Biostar Pharmaceuticals · NCT02253459 · 405 enrolled · China
- Sep 29, 2018Phase 2 study in Advanced Non-small Cell Lung CancerBeijing Biostar Pharmaceuticals · NCT03693547 · 26 enrolled · China
- Apr 5, 2019Phase 2 study in Advanced or Metastatic CRCBeijing Biostar Pharmaceuticals · NCT03906565 · 30 enrolled · China
- May 30, 2021Phase 1 study in Breast NeoplasmsBeijing Biostar Pharmaceuticals · NCT05052437 · 16 enrolled · China
- May 30, 2021Phase 2 study in Solid TumorBeijing Biostar Pharmaceuticals · NCT04911907 · 126 enrolled · China
- Dec 30, 2022Phase 2 study in Advanced Solid TumorBeijing Biostar Pharmaceuticals · NCT05700084 · 84 enrolled · China
- Dec 30, 2022Biostar Pharma's first study: phase 1 study in Advanced Solid TumorNew to Biostar PharmaBiostar Pharma · NCT05681000 · 28 enrolled · United States
- Dec 30, 20222 phase 3 studiesBeijing Biostar Pharmaceuticals · NCT05673629, NCT05673590
- Nov 6, 20242 phase 2 studiesBeijing Biostar Pharmaceuticals · NCT06683703, NCT06730581
- Jan 7, 2025Phase 2 study in Breast NeoplasmsBiostar Pharma · NCT06764940 · 120 planned · United States
- Feb 10, 2025Phase 3 study in Gastric or Gastroesophageal Junction AdenocarcinomaBeijing Biostar Pharmaceuticals · NCT06841679 · 778 planned · United States, China
- Jun 23, 2025Phase 2 study in Ovarian NeoplasmsBeijing Biostar Pharmaceuticals · NCT07044349 · 72 planned
- Jun 29, 2026Phase 3 study in Advanced Breast CancerBeijing Biostar Pharmaceuticals · NCT07684456 · 308 planned · China
Ahead
- Dec 1, 2026Primary completion: phase 2 study in Non-small Cell Lung Cancer Patients with Brain MetastasesBeijing Biostar Pharmaceuticals · NCT06683703
- Dec 31, 2026Primary completion: phase 2 study in Ovarian NeoplasmsBeijing Biostar Pharmaceuticals · NCT06730581
- Jan 15, 2027Primary completion: phase 2 study in Breast NeoplasmsBiostar Pharma · NCT06764940
- Mar 2027Primary completion: phase 2 study in Ovarian NeoplasmsBeijing Biostar Pharmaceuticals · NCT07044349
TargetBeta
“Tubulin stabiliser”ChEMBL 37, by rule
Other programs on the same 15 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Paclitaxelrule | Hoffmann-La Roche | phase 4 | 202 |
| Docetaxelrule | Sanofi | phase 4 | 199 |
| cabazitaxelrule | Sanofi | phase 4 | 21 |
| Vinblastinerule | Takeda | phase 4 | 4 |
| plinabulinrule | beyondspring-pharmaceuticals-inc | phase 3 | 8 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07684456Advanced Breast Cancer · China | 3 | Not yet recruiting | Beijing Biostar Pharmaceuticals | Mar 1, 2028 | 308 |
| NCT07044349Ovarian Neoplasms | 2 | Not yet recruiting | Beijing Biostar Pharmaceuticals | Mar 2027 | 72 |
| NCT06841679Gastric or Gastroesophageal Junction Adenocarcinoma · United States, China | 3 | Recruiting | Beijing Biostar Pharmaceuticals | Sep 1, 2030 | 778 |
| NCT06764940Breast Neoplasms · United States | 2 | Recruiting | Biostar Pharma | Jan 15, 2027 | 120 |
| NCT06730581Ovarian Neoplasms | 2 | Not yet recruiting | Beijing Biostar Pharmaceuticals | Dec 31, 2026 | 100 |
| NCT06683703Non-small Cell Lung Cancer Patients with Brain Metastases | 2 | Not yet recruiting | Beijing Biostar Pharmaceuticals | Dec 1, 2026 | 118 |
| NCT05700084Advanced Solid Tumor · China | 2 | Active, not recruiting | Beijing Biostar Pharmaceuticals | Oct 8, 2025 | 84 |
| NCT05681000Advanced Solid Tumor · United States | 1 | UNKNOWN | Biostar Pharma | Apr 15, 2024 | 28 |
| NCT05673629Breast Neoplasms · China | 3 | Recruiting | Beijing Biostar Pharmaceuticals | Jun 15, 2025 | 552 |
| NCT05673590Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Beijing Biostar Pharmaceuticals | Jun 15, 2025 | 612 |
| NCT05052437Breast Neoplasms · China | 1 | Completed | Beijing Biostar Pharmaceuticals | Jan 13, 2021 | 16 |
| NCT04911907Solid Tumor · China | 2 | Completed | Beijing Biostar Pharmaceuticals | May 31, 2025 | 126 |
| NCT03906565Advanced or Metastatic CRC · China | 2 | Suspended | Beijing Biostar Pharmaceuticals | Dec 31, 2023 | 30 |
| NCT03693547Advanced Non-small Cell Lung Cancer · China | 2 | Completed | Beijing Biostar Pharmaceuticals | Jun 25, 2021 | 26 |
| NCT02253459Breast Neoplasms · China | 3 | Completed | Beijing Biostar Pharmaceuticals | Sep 2016 | 405 |
| NCT00337649Breast Neoplasms · Spain | 2 | Completed | Hoffmann-La Roche | Jul 2007 | 27 |
| NCT00104130Prostatic Neoplasms · United States | 2 | Terminated | Bristol-Myers Squibb | 53 | |
| NCT00080509Lung Neoplasms | 2 | Terminated | Bristol-Myers Squibb | 85 | |
| NCT00030173Neoplasms · United States | 1 | Completed | Bristol-Myers Squibb | 45 |
How it is read
Names in the registry
- “Utidelone Capsule”, 7 entries
- “Utidelone”, 3 entries
- “Utidelone in combination with capecitabine”, 3 entries
- “utidelone injection”, 3 entries
- “Utidelone combined with Bevacizumab”, 3 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 6 studies
- Ovarian Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Brain Neoplasms, 1 study
- Lung Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.